What Fucidin Hydrocortisone Treats: Main Uses and Benefits

The primary clinical purpose of this combination cream is the management of symptoms related to inflammatory and irritative states that are complicated by secondary bacterial infection.

The cream is considered relevant for managing conditions characterized by periods of heightened symptoms, specifically eczema (including atopic eczema) and dermatitis, when a susceptible bacterial complication is present.

This combination is generally applied in clinical settings that involve acute or unstable symptom patterns, such as those presenting with pronounced redness, noticeable swelling, and intense or disruptive itching. By providing concurrent symptomatic management, the cream contributes to improved comfort and stability during periods of heightened symptoms, and may assist with maintaining functional stability in the affected area.

“This medicine is commonly used when symptoms related to skin inflammation and bacterial presence occur together.”

---

Quick Fact: Relevant for Infected Inflammatory Conditions

Fucidin Hydrocortisone's eligibility is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional use.

Who Must Not Use This Medicine (Contraindications)

The medicine is contraindicated and must not be used if there is a known hypersensitivity to fusidic acid, hydrocortisone, or any of the excipients. Use is also prohibited for managing skin conditions caused by non-bacterial pathogens, including viruses (e.g., cold sores, chickenpox) and fungi. Specific dermatological disorders like acne rosacea, perioral dermatitis, or skin manifestations of tuberculosis or syphilis are absolute contraindications.

---

Age-Related and Conditional Use

The cream is approved for adults and children; however, use in paediatric patients requires special care due to their greater risk of systemic side effects like Hypothalamic-Pituitary-Adrenal (HPA) axis suppression from the corticosteroid component. During pregnancy, use is permitted if clinically needed, but prolonged or extensive application must be avoided. When breastfeeding, the cream can be used, but applying it to the breast or nipple area is not recommended. Across all populations, long-term continuous topical therapy must be avoided, and application near the eyes requires caution due to the risk of glaucoma.

Interactions with other medicines and products

The official regulatory interaction profile for Fucidin Hydrocortisone, a topical cream, is fundamentally defined by the negligible systemic absorption of its two active components, Fusidic Acid and Hydrocortisone.

Systemic Drug-Drug Interactions

Regulatory documentation states that interactions with systemically administered medicinal products are considered minimal or unlikely due to the very low rate of absorption into the bloodstream. Consistent with this assessment, specific systemic metabolic interactions, such as those involving CYP enzymes or transporters, are not formally characterized in the product’s official prescribing information. Authorities note that dedicated systemic drug-interaction studies have not been performed for this topical formulation. Furthermore, no contraindicated combinations are explicitly documented for the cream in the context of systemic drug use.

Administration-Timing Interactions

The only defined constraint concerns co-application on the skin. A time separation is required between the application of Fucidin Hydrocortisone and the application of other topical products (such as moisturizers or emollients). This procedural constraint ensures optimal delivery and efficacy of the combination cream.

Food, Alcohol, and Supplements

Regulatory documentation confirms there are no known problems or documented interactions between this topical formulation and food, alcohol, herbal remedies, or supplements.

Fucidin Hydrocortisone exerts its action through two distinct pharmacodynamic mechanisms, corresponding to its two components: fusidic acid and hydrocortisone.

Targeted Bacterial Protein Synthesis Inhibition

Fusidic acid inhibits bacterial protein synthesis by binding to the elongation factor G (EF-G) on the ribosome. This interaction prevents the dissociation of EF-G from the ribosome, thereby blocking the necessary translocation and extension of the polypeptide chain. This action suppresses the biosynthetic machinery required for localized cellular proliferation.

Glucocorticoid Receptor-Mediated Anti-inflammatory Modulation

Hydrocortisone, a corticosteroid, acts as an agonist for the cytosolic glucocorticoid receptor (GR). The activated GR complex translocates to the nucleus and modulates gene transcription. This process primarily involves inducing the synthesis of anti-inflammatory proteins, such as lipocortin-1. Lipocortin-1, in turn, inhibits the activity of phospholipase A2. By blocking this early step, the synthesis of inflammatory mediators, including prostaglandins and leukotrienes, is reduced, contributing to decreased inflammatory signaling.

Instruction Map: How to use Fucidin Hydrocortisone

---

Administration Scope

Feature	Guideline
Route of administration	Topical (Cutaneous use)
Dosing schedule	Application of a small quantity or thin film to the affected skin area.
Timing in relation to meals (if applicable)	Not applicable, as the product is for topical use.
Preparation requirements (if applicable)	None required (used as supplied cream or ointment).
Age-group administration rules	Application principles are generally similar for adults and children; however, there are no data from controlled clinical trials on use in children under 3 years of age.
Missed-dose rules	If a scheduled application is missed, it should be applied as soon as the patient remembers, and then the regular application routine should be continued.
Special procedural conditions	The cream is to be gently massaged into the affected skin. Less frequent applications may be appropriate for lesions that are covered or occluded.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Topical (Cream/Ointment)
Frequency pattern	Twice daily or three times daily, for a short-term course.
Basis of instructions	Standardized administration protocols
Use-context constraints	A single treatment course should not normally exceed 14 days (2 weeks). Treatment must be stopped after 7 days if no clinical improvement is observed. Long-term continuous topical therapy must be avoided.

---

Resulting Procedural Structure

Step sequence:

• Apply the topical formulation (cream or ointment) to the area of the skin requiring treatment.
• Massage a small quantity of the preparation gently into the affected lesion.
• Repeat the application according to the specific frequency pattern.

Connection to the overall use protocol The instructions define Fucidin Hydrocortisone use as a localized, short-course intervention applied directly to the skin, with limitations on the total duration and application frequency. This procedural structure ensures that the administration aligns with established standards for proper use.

Research Evidence / Overview of Studies for Fucidin Hydrocortisone

---

Evidence for Use in Infected Eczema and Dermatitis

The research examining this combination product primarily consists of short-term Randomized Controlled Trials (RCTs) and scientific reviews that synthesize the findings from these trials. The research examined the combination cream in the context of the study of conditions characterized by inflammatory skin conditions, such as eczema and dermatitis, when the symptoms are complicated by a secondary bacterial infection. These studies research examined how the combination product was evaluated in measured outcomes compared to using the steroid component alone, other antibiotic creams, or a non-active cream (placebo).

In these research scenarios, investigators measured outcomes by monitoring how researchers monitored changes in the visible signs of skin inflammation and infection. Findings describe patterns observed in the studies over the short-term treatment period, which typically lasts one to two weeks. The research also explored how the presence of bacteria, such as Staphylococcus aureus, was monitored in the studied areas.

---

What Outcomes Were Measured in Clinical Trials?

To assess the research scenarios, studies focused on outcomes linked to inflammatory or irritative states and outcomes describing episodic or acute changes. Researchers used specific tools, such as the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM), to assign scores that monitor symptom intensity or variability. Studies monitored these scores over defined time intervals to understand the symptom patterns monitored in the observed populations.

Data collected included measurements of both the change in the inflammation and the change in the bacterial presence, providing a comprehensive data set for the specific conditions under which they were conducted.

---

Key Limitations and Areas of Uncertainty

Research has shown that the majority of the available evidence describes treatment durations of seven to fourteen days, meaning that follow-up durations were limited in many primary studies. The clinical trials provide limited information regarding the long-term patterns or extended course of monitored changes.

A central point of ongoing research discussion relates to the difference in clinical measurements when comparing the antibiotic component to the corticosteroid alone, especially for milder cases in children. While bacteriological changes may be observed, some systematic reviews indicate that the findings were mixed regarding a measurable clinical difference in overall skin severity scores. Furthermore, scientific research has focused on patterns related to antibiotic resistance that were observed in some studies with the widespread or repeated use of topical fusidic acid. This means that long-term effects are not fully established, and this area remains a focus for scientific monitoring.

Key Studies & References

1. A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community (CREAM study)

Common questions about Fucidin Hydrocortisone (FAQ)

---

Q: Can Fucidin Hydrocortisone be used for regular eczema?

Fucidin Hydrocortisone is formulated to treat inflammatory skin conditions, such as dermatitis and eczema, specifically when they are complicated by a secondary bacterial infection. The dual composition, combining a steroid and an antibiotic, is designed to address both the inflammation and the suspected or confirmed infection.

---

Q: Is there any evidence about using Fucidin Hydrocortisone on face or sensitive skin areas?

Regulatory documents describe the cream as cosmetically acceptable for application to the face and hands. However, due to the corticosteroid content, official information indicates that long-term use on the face should be avoided. Caution is also advised to ensure the cream does not come into contact with the eyes.

---

Q: Are there any ingredients in the cream that cause common allergies?

Official product information lists excipients (inactive ingredients) that have the potential to cause local skin reactions, such as contact dermatitis. These ingredients include butylhydroxyanisole (E320), cetyl alcohol, and potassium sorbate. A person with known sensitivities may wish to check the presence of these substances in the formulation.

---

Q: Can Fucidin Hydrocortisone be used for conditions like acne or fungal infections?

According to official prescribing information, the cream is contraindicated (must not be used) to treat conditions caused by non-bacterial pathogens, such as fungal or viral infections. It is also contraindicated for specific skin disorders, including acne rosacea.

---

Q: Can I use Fucidin Hydrocortisone for skin irritation that is not infected?

Fucidin Hydrocortisone is indicated for inflammatory skin conditions when there is a suspected or confirmed bacterial infection. The product's licensed use is based on its dual action, intended to address both the inflammation and the bacterial component.

---

Q: Is Fucidin Hydrocortisone used in combination with other treatments in certain cases?

Regulatory documents indicate that interactions with systemically administered (oral or injected) medications are considered minimal due to the low rate of absorption into the bloodstream. Official guidance indicates that if a skin infection is not successfully managed by a topical treatment, further systemic therapy may be required.

---

Q: Why is the duration of use for Fucidin Hydrocortisone often limited by regulators?

The treatment course is limited—typically not exceeding 14 days—due to risks associated with both active components. Official warnings cite that prolonged continuous use may increase the risk of systemic side effects from the steroid, such as HPA axis suppression, as well as the risk of antibiotic resistance developing.

---

Q: How does Fucidin Hydrocortisone compare to other hydrocortisone creams that don't have fusidic acid?

Fucidin Hydrocortisone is a fixed-dose combination product. The addition of fusidic acid, which is an antibiotic, is intended for cases where a topical corticosteroid alone is insufficient due to a bacterial infection. The cream is designed to be used in specific scenarios where both anti-inflammatory and antibacterial effects are required.

---

Q: Does the cream stain clothing or bedding?

Official safety warnings advise that fabrics, including clothing and bedding, contaminated with the cream or ointment can be highly flammable and pose a fire hazard. To reduce product build-up and the associated flammability risk, regular washing of contaminated materials is noted in official safety information.

---

Q: What if I accidentally swallow a small amount of Fucidin Hydrocortisone?

According to official product information, systemic consequences from an accidental oral intake are considered unlikely. The total quantity of active ingredients in a single tube does not typically exceed the daily amount used in systemic treatments. However, official regulatory documents advise seeking medical attention if a large quantity is swallowed.

---

Q: Are there documented cases of withdrawal effects after stopping Fucidin Hydrocortisone?

While the specific term 'withdrawal effects' may not appear on all product labels, regulatory bodies acknowledge that stopping topical corticosteroids, especially after extended periods of use, may lead to a recurrence or temporary worsening of the original skin condition.

---

Q: Does Fucidin Hydrocortisone contain parabens or other preservatives?

The cream contains excipients and preservatives, including butylhydroxyanisole (E320) and potassium sorbate. The complete and accurate list of all excipients and preservatives can be found in the official patient information leaflet or the Summary of Product Characteristics.

---

Q: What is the strength of the hydrocortisone in this particular combination cream?

The concentration of hydrocortisone acetate in the combination cream is 10 mg/g. This is equivalent to 1% weight for weight (w/w) hydrocortisone, placing it in the weak corticosteroid class.

---

Q: Are there any specific warnings about driving or operating machinery while using this product?

Official product information states that Fucidin Hydrocortisone is administered topically (on the skin) and has no or negligible influence on a person’s ability to drive or to use machinery.

---

Q: Can Fucidin Hydrocortisone be used on broken skin?

The cream is intended for application to the affected area of the skin or lesion. Official warnings state that use on large areas, open wounds, or severely broken skin for extended periods is generally discouraged. This caution is primarily due to the increased potential for systemic absorption of the corticosteroid component.

How to Store and Dispose of Fucidin Hydrocortisone?

Fucidin Hydrocortisone cream must be stored strictly according to its regulatory labeling to maintain stability and effectiveness.

---

Storage Requirements

The cream must be stored at temperatures not exceeding 25 C and must not be frozen. The product should be kept in its original container, which must be kept tightly closed.

Storage Constraint	Requirement
Temperature Limit	Below 25 C, Do not freeze
In-Use Stability	Discard 3 months after first opening
Safety Requirement	Keep out of the sight and reach of children

---

Disposal and Handling

Official instructions require disposal of unused or expired cream according to local regulations; it should not be thrown into household waste or wastewater. Additionally, a safety warning advises against smoking or approaching naked flames, as fabric contaminated with the cream poses a serious fire hazard.